Human hepatitis B virus mutants: significance of molecular changes

Chen, Wei Ning; Oon, Chong Jin

doi:10.1016/s0014-5793(99)00704-8

Cited by 43 publications

(37 citation statements)

References 76 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The real-time PCR assay was able to quantify HBV DNA even at low levels in subsequent follow-up samples and monitor the ef®cacy of antiviral treatment. Sensitive HBV DNA assays, such as the real-time PCR, allow also the detection of various HBV mutants that may remain undetectable using classical screening assays [Chen and Oon, 1999].…”

Section: Discussionmentioning

confidence: 99%

Real‐time PCR for detection and quantitation of hepatitis B virus DNA

Chen

Piiparinen

Seppänen

et al. 2001

Journal of Medical Virology

View full text Add to dashboard Cite

A sensitive and reproducible real-time PCR assay based on TaqMan technology was developed for the detection and quantitation of hepatitis B virus (HBV) DNA in serum, and compared with an "in-house" qualitative PCR assay. HBV DNA was measured in 125 serum samples from 76 hepatitis B patients, consisting of 22 patients with an acute infection, 20 patients with a previous history of hepatitis B infection, and 34 patients with a chronic hepatitis B. Four patients with a chronic infection were treated with either an IFN-alpha monotherapy or a combination of IFN-alpha and lamivudine. Twenty-nine sera from healthy individuals and non-hepatitis B patients served as negative controls. The assay was validated by using a 10-fold dilution series of the World Virological Quality Control (VQC) sample containing 3.73 x 10(7) genome equivalents per ml. The detection limit for the real-time PCR was 3.73 x 10(2) genome equivalents per ml (geq/ml), while it was 3.73 x 10(3) geq/ml for the in-house PCR. The real-time PCR assay had an 8-logarithm dynamic range spanning from 10(2) to 10(10) geq/ml. In clinical serum samples, the real-time PCR and the in-house PCR detected HBV DNA in 81% (101/125) and 66% (83/125) of samples, respectively. HBV DNA was not detected among the negative controls by either of these assays. In conclusion, real-time PCR is a sensitive, specific, and a reproducible approach for the detection and quantitation of HBV DNA in clinical serum samples, useful also for monitoring the efficacy of antiviral treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Real‐time PCR for detection and quantitation of hepatitis B virus DNA

Chen

Piiparinen

Seppänen

et al. 2001

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…A large body of evidence indicates that HBV can indirectly induce HCC by eliciting host immune responses against the infected hepatocytes [12,13]. Furthermore, several lines of evidence have demonstrated that naturally occurring mutants in the S region correlate with a more progressive form of liver disease [14,15]. In particular, antiviral drug therapies related to the C terminal truncated S proteins have been reported to potentially contribute to hepatocarcinogenesis through an increase in its transactivating capacity [16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Nucleotide change of codon 182 in the surface gene of hepatitis B virus genotype C leading to truncated surface protein is associated with progression of liver diseases

Lee

Kim

et al. 2012

Journal of Hepatology

View full text Add to dashboard Cite

“…These include noticeably HBV viral infections, which account for more than 80% of HCC cases in Asia (Chen and Oon, 1999;Wang et al, 2002). In the case of HBV infection, the risk of developing HCC for chronic HBV carriers is increased by a factor of 100 as compared with a non-infected individual (El-Serag et al, 2001).…”

Section: Introductionmentioning

confidence: 99%